Drug Trial Radar · NCT01568866
Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients
Last checked: Nov 20, 2026Latest source record: Nov 14, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
929
Actual
Start
Jun 20, 2012
Primary completion
Nov 10, 2014
Study completion Feb 5, 2018
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Apr 2, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to compare progression-free survival in patients with multiple myeloma who relapsed after 1 to 3 prior therapies treated with carfilzomib plus dexamethasone or bortezomib plus dexamethasone.
Conditions
- Multiple Myeloma
Interventions
CarfilzomibDrug
Carfilzomib is administered over 30 minutes as an infusion.
BortezomibDrug
Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
DexamethasoneDrug
Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free SurvivalTime frame: From randomization until the data cut-off date of 10 November 2014; median follow-up time for PFS was 11.1.and 11.9 months in the bortezomib and carfilzomib arms respectively
Locations
241 sites in 27 countries. Site status is shown where the registry gives one.
Providence St. Joseph Medical Center
Burbank, California
UCSD Moore Cancer Center
La Jolla, California
UCLA Medical Center
Los Angeles, California
Central Coast Medical Oncology Group
Santa Maria, California
Colorado Blood Cancer Institute
Denver, Colorado
MAB Oncology/Hematology
Melbourne, Florida
Palm Beach Cancer Institute
West Palm Beach, Florida
Winship Cancer Institute
Atlanta, Georgia
Hematology Oncology of Indiana, PC
Indianapolis, Indiana
Center for Cancer and Blood Disorders
Bethesda, Maryland
Associates in Oncology/Hematology PC
Rockville, Maryland
University of Michigan
Ann Arbor, Michigan
University of Kansas
Kansas City, Missouri
Hackensack University Medical Ctr
Hackensack, New Jersey
Clinical Research Alliance Inc.
New York, New York
Weill Cornell Medical College
New York, New York
Montefiore Medical Center
The Bronx, New York
Wake Forest University Health Sciences, Section on Hematology and Oncology
Winston-Salem, North Carolina
Gabrail Cancer Center
Canton, Ohio
The Christ Hospital
Cincinnati, Ohio
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania
Hematology/Oncology Associates of SC
Greenville, South Carolina
Vanderbilt Ingram Cancer Center
Nashville, Tennessee
MD Anderson
Houston, Texas
The Methodist Cancer Center
Houston, Texas
Scott & White Memorial Hospital
Temple, Texas
University of Utah School of Medicine
Salt Lake City, Utah
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
St. Vincent's Public Hospital Sydney
Darlinghurst, New South Wales, Australia
Saint George Hospital
Kogarah, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Calvary Mater Newcastle
Waratah, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia
Haematology & Oncology Clinics of Australia
South Brisbane, Queensland, Australia
Haematology and Oncology Clinics of Australia at Chermside
South Brisbane, Queensland, Australia
Haematology and Oncology Clinics of Australia at Wesley
South Brisbane, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Showing 40 of 241 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.